Archive | Maryland Life Sciences Community

Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion

Catalent_Biologics-1080x675

Will provide new expertise and capabilities in one of the fastest-growing areas of healthcare, positioning Catalent for accelerated long-term growth SOMERSET, N.J. and BALTIMORE, M.D. – April 15, 2019 – Catalent, Inc. (NYSE: CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, […]

Comments Off on Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion Continue Reading →

PressComm PR Client Rachel King, CoFounder and CEO, GlycoMimetics Inc. Featured on PharmaVOICE Podcast

King-Rachel-PVcom-FeaturedImage630x315-560x315

Rachel King has charted a unique career — from consultant to VC to startup to now CEO — and is leading a pioneering company in the use of glycobiology technology. Click here to listen to the podcast via Pharmavoice.com”

Comments Off on PressComm PR Client Rachel King, CoFounder and CEO, GlycoMimetics Inc. Featured on PharmaVOICE Podcast Continue Reading →

UM Ventures Announces UMB Entrepreneur of the Year

Griffith_Bartley3

After 1,250 heart transplants and 685 lung transplants, one would think Bartley P. Griffith could rest easy at night, knowing he had done everything possible for his patients. But for the past 20-plus years, Griffith has felt a void. As he expressed when he was named UMB Researcher of the Year in 2010 “my own […]

CoapTech, LLC, and University of Maryland, Baltimore Set Stage to Commercialize Novel Procedure for Placing Feeding Tubes

umventures-logo-trans

– Start-up Company Developing Safer, Less Expensive Gastrostomy Method – CoapTech Receives Maryland Innovative Initiative Award to Further Advance the Technology BALTIMORE, Nov. 29, 2016 /PRNewswire/ — University of Maryland (UM) Ventures and CoapTech, LLC, announced today that the University of Maryland, Baltimore (UMB) has granted CoapTech exclusive licensing rights for the commercial development of […]

Comments Off on CoapTech, LLC, and University of Maryland, Baltimore Set Stage to Commercialize Novel Procedure for Placing Feeding Tubes Continue Reading →

Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder

gliknik

Gliknik Inc., a privately held biopharmaceutical company, today announced that its licensee Pfizer Inc. (NYSE: PFE) has received notification from the U.S. Food and Drug Administration (FDA) that its autoimmune candidate drug GL-2045, a recombinant Intravenous Immune Globulin (IVIG)-mimetic, has been granted orphan drug designation for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). CIDP is a rare […]

Comments Off on Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder Continue Reading →

Symbiomix Therapeutics’ First Pivotal Trial Results for SYM-1219 for Bacterial Vaginosis Presented at IDSOG

SBMX-logo-RGB

Positive results of Symbiomix Therapeutics’ first pivotal trial for lead drug candidate SYM-1219, a single-dose, oral product candidate for the treatment of bacterial vaginosis (BV), were presented today at the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting in Portland, Oregon. The results from the multi-center, randomized Phase 2 trial showed that a […]

Comments Off on Symbiomix Therapeutics’ First Pivotal Trial Results for SYM-1219 for Bacterial Vaginosis Presented at IDSOG Continue Reading →

Vtesse, Inc. Announces Preliminary Data from Ongoing Phase 1 Study of VTS-270 for Treatment of Niemann-Pick Disease Type C

Vtesse, Inc. logo (PRNewsFoto/Vtesse, Inc.)

Post-Hoc Analyses of Data Show Preliminary Evidence of Overall Disease Stabilization with Improvement in Several Disease Domains Gaithersburg, MD, August 6, 2015 – Vtesse, Inc. announced preliminary results today from an open-label Phase 1 clinical trial with VTS-270 (a formulation of (2-hydroxypropyl)-beta-cyclodextrin) for treatment of Niemann-Pick Disease Type C (NPC) conducted by researchers at the […]

Comments Off on Vtesse, Inc. Announces Preliminary Data from Ongoing Phase 1 Study of VTS-270 for Treatment of Niemann-Pick Disease Type C Continue Reading →

BioHealth Innovation’s Relevant Health Accelerator Recognized As One Of The Nation’s Leading Startup Accelerators By The U.S. Small Business Administration

BHI_RELEVANT

BioHealth Innovation’s Relevant Health, a recently launched health technology startup accelerator focused on bringing products to market, participated in the U.S. Small Business Administration’s (SBA) Second Annual Growth Accelerator Fund Competition. Relevant Health was among 80 winners from a pool of 400 applicants from across the country, including all 50 states, the District of Columbia […]

Comments Off on BioHealth Innovation’s Relevant Health Accelerator Recognized As One Of The Nation’s Leading Startup Accelerators By The U.S. Small Business Administration Continue Reading →

Technology for detecting bowel disease gets licensing deal from UM Ventures

biomecite logo

Technical.ly Baltimore Biomecite Diagnostics signed an exclusive option with UM Ventures to license technology that’s designed to determine if a patient has inflammatory bowel diseases (IBD) through genetics. Biomecite’s technology can analyze patient stool samples for specific genetic sequences to detect diseases like IBD, ulcerative colitis (UC) and Crohn’s disease. Currently, procedures like a colonoscopy […]

Comments Off on Technology for detecting bowel disease gets licensing deal from UM Ventures Continue Reading →

Pharmaceutical firm Symbiomix Therapeutics closes third tranche of $41 million Series A

SBMX-logo-RGB

Baltimore Business Journal Pharmaceutical firm Symbiomix Therapeutics has closed the third and final tranche of $41 million in funding. Investors in the Series A round included OrbiMed, Fidelity BioSciences and HBM Partners. The $41 million round is comprised of $32.5 million in equity and $8.5 million in debt. The third tranche was $13 million in […]

Comments Off on Pharmaceutical firm Symbiomix Therapeutics closes third tranche of $41 million Series A Continue Reading →